Fenofibrate in diabetic retinopathy and nephropathy
Fenofibrate, a peroxisome proliferator activated receptor (PPAR)-α agonist, is being repositioned as a multitarget therapy for diabetic retinopathy (DR) and nephropathy (DN), offering benefits that extend beyond its classical lipid-lowering role.
Emerging clinical and molecular evidence reveals pleiotropic actions of fenofibrate, including anti-inflammatory, antioxidant, neuroprotective, and antifibrotic effects, via both PPAR-α-dependent and -independent pathways.
Next-generation selective PPAR-α modulators and combination therapies further expand the therapeutic potential of fenofibrate for diabetic microvascular complications.
Advanced nanoformulations enhance the retinal bioavailability of fenofibrate, overcoming the challenges of effective ocular drug delivery.
https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(25)00157-9
